Another class of anti-diabetics are the modulators of incretins, that include GLP-1 receptor agonists and DPP-4 inhibitors (vildagliptin or sitagliptin) used for T2D and obesity (in the case of GLP-1 agonists). This evidence concerns the gene GCG and Obesity.